---
title: "Processa Pharmaceuticals | 10-K: FY2025 Revenue: USD 0"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/283982824.md"
datetime: "2026-04-24T10:37:53.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/283982824.md)
  - [en](https://longbridge.com/en/news/283982824.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/283982824.md)
---

# Processa Pharmaceuticals | 10-K: FY2025 Revenue: USD 0

Revenue: As of FY2025, the actual value is USD 0.

EPS: As of FY2025, the actual value is USD -10.36.

EBIT: As of FY2025, the actual value is USD -14.1 M.

Processa Pharmaceuticals, Inc. operates as a single reportable segment focused on developing next-generation cancer therapy drugs, thus all reported metrics apply to this segment .

#### Operational Metrics

-   The operating loss for Processa Pharmaceuticals, Inc. was - $13,988,505 for the year ended December 31, 2025, an increase from - $12,051,206 for the year ended December 31, 2024 .
-   Research and Development Expenses increased by $541,000 to $7,810,337 in 2025 from $7,269,146 in 2024, primarily due to an approximately $790,000 increase for ongoing testing and related expenses for the NGC-Cap Phase 1B trial and the initiation of the Phase 2 trial, offset by a $248,000 decrease in salaries and other payroll-related expenses due to a staff reduction .
-   General and Administrative Expenses increased by approximately $1.4 million to $6,178,168 in 2025 from $4,782,060 in 2024, mainly driven by a $474,000 increase in salaries, a $322,000 increase in employee stock-based compensation, a $313,000 increase in professional fees, a $164,000 increase in franchise taxes, and a $174,000 increase in investment fees, insurance, and other miscellaneous costs .
-   Other Income was $20,000 in 2025, compared to $0 in 2024 .
-   An unrealized gain on digital assets of $295,180 was recognized in 2025, compared to $0 in 2024 .
-   Interest and Dividend Income, net, decreased to $109,491 in 2025 from $201,088 in 2024 .
-   The net loss was - $13,563,834 in 2025, compared to - $11,850,118 in 2024 .
-   The accumulated deficit was approximately $100.8 million at December 31, 2025 .

#### Cash Flow

-   Net Cash Used in Operating Activities was - $11,385,195 in 2025, an increase from - $11,245,042 in 2024, primarily due to increased costs for the NGC-Cap Phase 2 trial, higher salaries, payroll-related expenses, and professional fees .
-   Net Cash Used in Investing Activities was - $850,000 in 2025, primarily for the purchase of digital assets, compared to - $3,244 in 2024 for equipment purchases .
-   Net Cash Provided by Financing Activities was $16,580,825 in 2025, an increase from $7,733,414 in 2024, which included $10.6 million from public offerings, $3.0 million from ATM offerings, $1.2 million from a Securities Purchase Agreement, and $1.8 million from warrant exercises .

#### Unique Metrics

-   Cash and Cash Equivalents held by Processa Pharmaceuticals, Inc. were $5.5 million at December 31, 2025 .
-   As of December 31, 2025, Processa Pharmaceuticals, Inc. held 27,101,000 CHZ tokens with a cost basis of $850,000 and a fair value of $1,145,180 . By March 13, 2026, the company owned 37,517,000 CHZ tokens with a fair value of $1.4 million after an additional purchase of 10,416,000 CHZ tokens for $500,000 on January 12, 2026 .
-   Prepaid Expenses for clinical trials were $1.0 million at December 31, 2025, representing advanced payments to CROs and vendors for the NGC-Cap Phase 2 clinical trial .

#### Outlook / Guidance

Processa Pharmaceuticals, Inc. anticipates needing to raise additional capital in the second quarter of 2026 to fund its operations and continue the planned development of its NGC drugs in the first half of 2026 . The company expects research and development costs and general and administrative expenses to increase, leading to continued negative cash flows from operating activities for the foreseeable future . Absent additional funding, there is substantial doubt about Processa Pharmaceuticals, Inc.’s ability to continue as a going concern for more than one year from the financial statement issuance date .

### Related Stocks

- [PCSA.US](https://longbridge.com/en/quote/PCSA.US.md)

## Related News & Research

- [Your new car is getting harder and more expensive to fix. This bill could help.](https://longbridge.com/en/news/289544837.md)
- [Greg Abbott wants data centers to stop passing the bill to Texans](https://longbridge.com/en/news/289389284.md)
- [Is Schwab’s 24/7 Crypto Futures and $1 Fractional Access Altering The Investment Case For Charles Schwab (SCHW)?](https://longbridge.com/en/news/289119714.md)
- [From Token-maxxing To Token-panic: Citrini Warns AI Goldilocks Narrative Hitting A Wall](https://longbridge.com/en/news/289342597.md)
- [Front Month Nymex Crude Fell 6.25% This Week to Settle at $84.88 — Data Talk](https://longbridge.com/en/news/289631837.md)